Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

Area of Science:

• Pediatric Health
• Hematology
• Quality of Life Research

Background:

• Assessing changes in health status and identifying meaningful improvements are crucial for patient-centered outcomes using health-related quality of life (HRQL) instruments.
• The PedsQL™ Sickle Cell Disease module is a validated and reliable disease-specific HRQL instrument.

Purpose of the Study:

• To determine the longitudinal validity of the PedsQL™ Sickle Cell Disease module.
• To identify changes in HRQL that are meaningful to pediatric patients with sickle cell disease.

Main Methods:

• A multi-center prospective trial enrolled children aged 4-21 with sickle cell disease during acute vaso-occlusive crises.
• HRQL assessments were conducted at three time points: in the Emergency Department, one week post-discharge, and at 1-3 months post-discharge.
• Longitudinal validity and meaningful change were assessed using distribution-based (effect size, SEM) and anchor-based (global change assessment) methods.

Main Results:

• Moderate effect sizes were found across most HRQL domains, indicating responsiveness to change.
• The standard error of measurement (SEM) varied from 3.8-14.6, with over 50% of patients showing improvement of at least 1 SEM in total HRQL score.
• A HRQL change score of 7-10 indicated minimal perceived improvement in pain domains, while a score of 18 or greater suggested moderate to large improvement.

Conclusions:

• The PedsQL™ Sickle Cell Disease Module demonstrates responsiveness to HRQL changes in pediatric patients with sickle cell disease during acute vaso-occlusive crises.
• The study confirms the longitudinal validity of the module and establishes parameters for meaningful change in HRQL for this population.